

10 - 15 - 01

Express Mail Label No.: EL862266190US

Date of Deposit: October 12, 2001

Attorney Docket No. 22058-521

Receipt  
RECEIVED

NOV 02 2001

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Keith *et al.*

SERIAL NUMBER: 09/521,696

FILING DATE: March 9, 2000

FOR: USE OF INTERLEUKIN-11 TO PREVENT IMMUNE-MEDIATED  
CYTOTOXICITY

EXAMINER: Not Yet Assigned

ART UNIT: 1647

Application Processing Division's  
Customer Correction Branch  
Assistant Commissioner for Patents  
Washington, D.C. 20231


**TRANSMITTAL LETTER**

Transmitted herewith for filing in the above-referenced patent application are the following documents:

- Request for corrected filing receipt (1 page);
- Copy of filing receipt marked with correction (3 pages); and
- Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311, Ref. No. 22058-521. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,  
  
Ivor R. Elrifi, Reg. No. 39,529  
David E. Johnson, Reg. No. 41,874  
Attorneys for Applicants  
c/o MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY AND POPEO, P.C.

One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241



Express Mail Label No.: EL862266190US  
Date of Deposit: October 12, 2001

Attorney Docket No.: 22058-521

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 02 2001

TECH CENTER 1600/2900

APPLICANTS: Keith *et al.*  
SERIAL NUMBER: 09/521,696 EXAMINER: Not Yet Assigned  
FILING DATE: March 9, 2000 ART UNIT: 1647  
FOR: USE OF INTERLEUKIN-11 TO PREVENT IMMUNE-MEDIATED CYTOTOXICITY

Office of Initial Patent Examiner's  
Customer Service Center  
Assistant Commissioner for Patents  
Washington, D.C. 20231

REQUEST FOR CORRECTED FILING RECEIPT

1. Applicants request a Corrected Filing Receipt for the above-mentioned patent application. Applicants enclose a copy of the Filing Receipt with the corrections noted thereon. Issuance of a corrected filing receipt is respectfully requested.
2. There are errors with respect to the following data, which are incorrectly entered.

<i>Error in</i>	<i>Correct data</i>
Attorney Name	Ivor R. Elrifi, Ph.D.
Attorney Address	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. One Financial Center Boston, MA 02111
Attorney Docket No.	22058-521

3. The correction is not due to any error by Applicants and Applicants believe that no fee is due. However, the Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to Deposit Account No. 50-0311, Ref. No. 22058-521.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529  
David E. Johnson, Reg. No. 41,874  
Attorneys for Applicants  
c/o MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY AND POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Dated: October 12, 2001



## UNITED STATES PATENT AND TRADEMARK OFFICE

DEJ

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov



APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE RECD	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/521,696	03/09/2000	1647	820	GI-5345	3	9	3

22058-521

CONFIRMATION NO. 2455

CORRECTED FILING RECEIPT

  
OC000000006362591

RAY E. BRADY  
AMERICAN HOME PRODUCTS CORPORATION  
PATENT DEPARTMENT- 2B  
ONE CAMPUS DRIVE  
PARSIPPANY, NJ 07054

RECEIVED

AUG 24 2001

22058-521

a

IVOR R. ELRIFI, PH.D.  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY AND POPEO, P.C.  
ONE FINANCIAL CENTER, BOSTON, MA 02111

MINTZ LEVIN, BOSTON  
PATENT DOCKET DEPT.

Date Mailed: 07/31/2001

Receipt is acknowledged of a CPA in this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

James Keith, Andover, MA;  
Joseph M. Carroll, Manchester, MA;  
Jordan S. Pober, Guilford, CT;

Done By	
<input type="checkbox"/> Data Entry	_____
<input type="checkbox"/> Docket Entry	_____
<input type="checkbox"/> Docket Cross Off	_____
<input checked="" type="checkbox"/> Previously Entered	JFH
<input type="checkbox"/> No Docketing Req	_____
<input type="checkbox"/> ELITE	_____
<input type="checkbox"/> Annuities	_____

## Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/124,024 03/11/1999

## Foreign Applications

If Required, Foreign Filing License Granted 05/18/2000

CPA filed on: 05/10/2001

RECEIVED

Projected Publication Date: 11/08/2001

AUG 02 2001


Non-Publication Request: No

R. L. CROMER

Early Publication Request: No

## Title

Use of interleukin-11 to prevent immune-mediated cytotoxicity



**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Cod of Federal Regulations, 5.11 & 5.15**

**RECEIVED**

NOV 02 2001

TECH CENTER 1600/2900

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 36 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231